Echinacea purpurea Polysaccharide Reduces the Latency Rate in Herpes Simplex Virus Type-1 InfectionsGhaemi A.a, b · Soleimanjahi H.d · Gill P.c · Arefian E.d · Soudi S.e · Hassan Z.e
aFaculty of Medicine, Golestan University of Medical Sciences and Health Care, Gorgan, bYoung Researchers’ Club, Tehran Science and Research Campus, IAU, cDepartment of Nanobiotechnology, Faculty of Basic Sciences, and Departments of dVirology and eImmunology, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran
Amir Ghaemi, Hoorieh Soleimanjahi
Department of Virology, School of Medical Sciences, Tarbiat Modares University
P.O. Box 14115-111, Tehran (Iran)
Tel. +98 21 8801 3561, Fax +98 21 8801 3030
E-Mail firstname.lastname@example.org or email@example.com
Do you have an account?
Objective: During the latency period of herpes simplex virus type-1 (HSV-1), the virus can occasionally reactivate, travel back to the eye and cause recurrent ocular disease. As this condition arises from the ability of HSV-1 to produce a dormant infection, effective medication to prevent the virus enter a latent state should prevent it. In this study, we applied Echinacea polysaccharide (EP) fraction as prophylactic mediator for latency prevention. Methods: In order to investigate the protective properties of EP, we evaluated its immunostimulatory functions on different immune aspects that play important roles in latency prevention (particularly IFN-γ as one of the main indicators of cellular immunity and latency). Finally, we assessed establishment of latency by detection of thymidine kinase gene in trigeminal ganglia of BALB/c mice. Results: We demonstrated that EP promotes immune response, leading to a reduced latency rate, and it has a promising effect on latency prevention. Conclusion: EP was able to exert an antiviral action on the development of recurrent HSV-1 disease when supplied prior to infection.
© 2009 S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.